Skip to Content

Empliciti Approval History

  • FDA approved: Yes (First approved November 30th, 2015)
  • Brand name: Empliciti
  • Generic name: elotuzumab
  • Dosage form: Injection
  • Company: Bristol-Myers Squibb Company and AbbVie
  • Treatment for: Multiple Myeloma

Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

Development History and FDA Approval Process for Empliciti

Nov 30, 2015Approval FDA Approves Empliciti (elotuzumab) for Multiple Myeloma
Sep  1, 2015FDA Accepts for Priority Review the BLA for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma
Jun  2, 2015Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data
May 19, 2014BMS and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab for Multiple Myeloma
Jun 17, 2013Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab
Dec  7, 2010Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma Presented at 52nd American Society of Hematology Annual Meeting
Dec  7, 2009Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.